Twist Bioscience Corporation

NasdaqGS:TWST Stock Report

Market Cap: US$2.8b

Twist Bioscience Management

Management criteria checks 3/4

Twist Bioscience's CEO is Emily Leproust, appointed in Apr 2013, has a tenure of 11.67 years. total yearly compensation is $8.00M, comprised of 8.6% salary and 91.4% bonuses, including company stock and options. directly owns 0.48% of the company’s shares, worth $13.57M. The average tenure of the management team and the board of directors is 2.7 years and 8.1 years respectively.

Key information

Emily Leproust

Chief executive officer

US$8.0m

Total compensation

CEO salary percentage8.6%
CEO tenure11.7yrs
CEO ownership0.5%
Management average tenure2.7yrs
Board average tenure8.1yrs

Recent management updates

Recent updates

Twist Bioscience Corporation's (NASDAQ:TWST) Shareholders Might Be Looking For Exit

Nov 30
Twist Bioscience Corporation's (NASDAQ:TWST) Shareholders Might Be Looking For Exit

Twist Bioscience: Path To Profitability Beginning To Take Shape

Nov 29

Twist Bioscience: A Post-Earnings Assessment

Nov 18

Twist Bioscience's Earnings Preview: Partnerships And Valuation Make It A 'Buy'

Nov 08

Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business

Sep 25
Twist Bioscience (NASDAQ:TWST) Is In A Strong Position To Grow Its Business

Investors Aren't Buying Twist Bioscience Corporation's (NASDAQ:TWST) Revenues

Aug 20
Investors Aren't Buying Twist Bioscience Corporation's (NASDAQ:TWST) Revenues

Twist Bioscience: Lowered Biopharma Expectations Amid Financial Strain (Rating Downgrade)

Aug 04

Twist Bioscience: Growing Customer Base And Technology Platform Make Me Like This Stock

Jul 26

We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth

Jun 10
We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth

Twist Bioscience Corporation (NASDAQ:TWST) Shares Fly 29% But Investors Aren't Buying For Growth

May 04
Twist Bioscience Corporation (NASDAQ:TWST) Shares Fly 29% But Investors Aren't Buying For Growth

Twist Bioscience: NGS Is Taking Off

May 03

Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Feb 27
Twist Bioscience Corporation (NASDAQ:TWST) Surges 26% Yet Its Low P/S Is No Reason For Excitement

Twist Bioscience: Strong Performance In A Soft Market

Feb 07

Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

Jan 31
Here's Why Shareholders May Want To Be Cautious With Increasing Twist Bioscience Corporation's (NASDAQ:TWST) CEO Pay Packet

We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate

Jan 22
We're Not Very Worried About Twist Bioscience's (NASDAQ:TWST) Cash Burn Rate

Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Dec 18
Twist Bioscience Corporation's (NASDAQ:TWST) Price Is Right But Growth Is Lacking After Shares Rocket 44%

Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans

Oct 05
Twist Bioscience (NASDAQ:TWST) Is In A Good Position To Deliver On Growth Plans

We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth

Jul 07
We Think Twist Bioscience (NASDAQ:TWST) Can Afford To Drive Business Growth

CEO Compensation Analysis

How has Emily Leproust's remuneration changed compared to Twist Bioscience's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$209m

Jun 30 2024n/an/a

-US$220m

Mar 31 2024n/an/a

-US$192m

Dec 31 2023n/an/a

-US$206m

Sep 30 2023US$8mUS$685k

-US$205m

Jun 30 2023n/an/a

-US$209m

Mar 31 2023n/an/a

-US$213m

Dec 31 2022n/an/a

-US$214m

Sep 30 2022US$6mUS$665k

-US$218m

Jun 30 2022n/an/a

-US$208m

Mar 31 2022n/an/a

-US$188m

Dec 31 2021n/an/a

-US$165m

Sep 30 2021US$1mUS$590k

-US$152m

Jun 30 2021n/an/a

-US$135m

Mar 31 2021n/an/a

-US$123m

Dec 31 2020n/an/a

-US$117m

Sep 30 2020US$7mUS$519k

-US$140m

Jun 30 2020n/an/a

-US$147m

Mar 31 2020n/an/a

-US$147m

Dec 31 2019n/an/a

-US$141m

Sep 30 2019US$8mUS$477k

-US$108m

Jun 30 2019n/an/a

-US$96m

Mar 31 2019n/an/a

-US$86m

Dec 31 2018n/an/a

-US$77m

Sep 30 2018US$525kUS$362k

-US$71m

Compensation vs Market: Emily's total compensation ($USD8.00M) is about average for companies of similar size in the US market ($USD6.65M).

Compensation vs Earnings: Emily's compensation has increased whilst the company is unprofitable.


CEO

Emily Leproust (51 yo)

11.7yrs

Tenure

US$7,998,637

Compensation

Dr. Emily Marine Leproust, Ph.D. serves as Independent Director at CM Life Sciences, Inc. since September 2, 2020. She serves as an Independent Director at GeneDx Holdings Corp. (formerly known as Sema4 Ho...


Leadership Team

NamePositionTenureCompensationOwnership
Emily Leproust
Co-Founder11.7yrsUS$8.00m0.48%
$ 13.6m
Patrick Finn
President & COO2.2yrsUS$5.23m0.13%
$ 3.6m
Paula Green
Senior Vice President of Human Resources8.8yrsUS$2.49m0.062%
$ 1.8m
William Banyai
Senior VP of Advanced Development4.9yrsUS$2.82m0.44%
$ 12.4m
Adam Laponis
Chief Financial Officerless than a yearno data0.012%
$ 332.1k
Robert Werner
VP & Chief Accounting Officer1.6yrsno data0.018%
$ 512.2k
Siyuan Chen
Chief Technology Officer3.8yrsno datano data
Michael Fero
Chief Information Officerless than a yearno datano data
Dennis Cho
Senior VP3.3yrsUS$1.96m0.068%
$ 1.9m
Nicole Moreno
Senior Vice President of Sales & Supportless than a yearno datano data
Angela Bitting
Chief ESG Officer & Senior VP of Corporate Affairs3.8yrsno datano data
Mark Buck
Senior Vice President of Operations1.2yrsno datano data

2.7yrs

Average Tenure

52yo

Average Age

Experienced Management: TWST's management team is considered experienced (2.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Emily Leproust
Co-Founder11.7yrsUS$8.00m0.48%
$ 13.6m
William Banyai
Senior VP of Advanced Development11.7yrsUS$2.82m0.44%
$ 12.4m
Keith Crandell
Independent Director11.2yrsUS$272.49k0.16%
$ 4.5m
Robert Chess
Lead Independent Director10.4yrsUS$303.98k0.11%
$ 3.1m
Nelson Chan
Independent Director5.6yrsUS$284.99k0.030%
$ 856.5k
Robert Ragusa
Independent Director8.1yrsUS$271.34k0.023%
$ 651.9k
Jan Johannessen
Independent Director6.2yrsUS$284.99k0.020%
$ 556.9k
Melissa Starovasnik
Independent Director3.3yrsUS$276.61k0.018%
$ 521.9k
Xiaoying Mai
Independent Director6.4yrsUS$269.99k0.043%
$ 1.2m

8.1yrs

Average Tenure

64yo

Average Age

Experienced Board: TWST's board of directors are considered experienced (8.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 14:58
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Twist Bioscience Corporation is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Catherine Ramsey SchulteBaird
Luke SergottBarclays
Gaurav GoparajuBerenberg